Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain.
Rheumatology Division, Hospital Universitario La Princesa, IIS-IP, Madrid, Spain.
Sci Rep. 2017 Sep 5;7(1):10525. doi: 10.1038/s41598-017-10915-9.
Several protein tyrosine phosphatase non-receptor 22 (PTPN22) single-nucleotide polymorphisms (SNPs) have been significantly related with rheumatoid arthritis (RA) susceptibility. Nevertheless, its potential influence on PTPN22 expression in RA has not been completely elucidated. Furthermore, PTPN22 binds to C-Src tyrosine kinase (CSK) forming a key complex in autoimmunity. However, the information of CSK gene in RA is scarce. In this study, we analyzed the relative PTPN22 and CSK expression in peripheral blood from 89 RA patients and 43 controls to determine if the most relevant PTPN22 (rs2488457, rs2476601 and rs33996649) and CSK (rs34933034 and rs1378942) polymorphisms may influence on PTPN22 and CSK expression in RA. The association between PTPN22 and CSK expression in RA patients and their clinical characteristics was also evaluated. Our study shows for the first time a marked down-regulation of PTPN22 expression in RA patients carrying the risk alleles of PTPN22 rs2488457 and rs2476601 compared to controls (p = 0.004 and p = 0.007, respectively). Furthermore, CSK expression was significantly lower in RA patients than in controls (p < 0.0001). Interestingly, a reduced PTPN22 expression was disclosed in RA patients with ischemic heart disease (p = 0.009). The transcriptional suppression of this PTPN22/CSK complex may have a noteworthy clinical relevance in RA patients.
几种蛋白酪氨酸磷酸酶非受体 22(PTPN22)单核苷酸多态性(SNP)与类风湿关节炎(RA)易感性显著相关。然而,其对 RA 中 PTPN22 表达的潜在影响尚未完全阐明。此外,PTPN22 与 C-Src 酪氨酸激酶(CSK)结合形成自身免疫中的关键复合物。然而,RA 中 CSK 基因的信息很少。在这项研究中,我们分析了 89 例 RA 患者和 43 例对照者外周血中相对 PTPN22 和 CSK 的表达,以确定最相关的 PTPN22(rs2488457、rs2476601 和 rs33996649)和 CSK(rs34933034 和 rs1378942)多态性是否会影响 RA 中 PTPN22 和 CSK 的表达。还评估了 RA 患者 PTPN22 和 CSK 表达与临床特征之间的相关性。我们的研究首次表明,与对照组相比,携带 PTPN22 rs2488457 和 rs2476601 风险等位基因的 RA 患者 PTPN22 表达明显下调(p=0.004 和 p=0.007,分别)。此外,RA 患者 CSK 的表达明显低于对照组(p<0.0001)。有趣的是,缺血性心脏病(p=0.009)的 RA 患者 PTPN22 表达降低。该 PTPN22/CSK 复合物的转录抑制可能对 RA 患者具有重要的临床意义。